Physician profile
Mohammad Chowdhury
NPI 1639335607
$3,469.31
in general payments reported to CMS, 2019-2025
21 companies · $721 in 2025
The $721 reported for 2025 was more than what 76% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,007 · 2020: $235 · 2021: $262 · 2022: $111 · 2023: $698 · 2024: $436 · 2025: $721.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,303 · Travel and Lodging: $552.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,302.87 |
| Travel and Lodging | $551.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $726.84 | 2019-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Abbott Laboratories | $551.77 | 2023-2024 | Thoratec Heartmate 3 Lvas Implant Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $474.33 | 2022-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $341.44 | 2019-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Alkermes, INC. | $253.33 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $224.33 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $180.81 | 2019-2021 | |
| Lundbeck LLC | $147.94 | 2019-2023 | Rexulti |
| Axsome Therapeutics, INC. | $119.20 | 2025 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $105.50 | 2025 | Cobenfy |
| Abbvie INC. | $48.08 | 2022-2023 | Vraylar |
| Takeda Pharmaceuticals U.S.A., INC. | $44.43 | 2019 | |
| Ironshore Pharmaceuticals INC. | $42.52 | 2019 | |
| Indivior INC. | $41.86 | 2020 | |
| Acadia Pharmaceuticals INC | $33.66 | 2025 | Nuplazid |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Orexo US, INC. | $30.46 | 2019 | |
| Vanda Pharmaceuticals INC. | $29.47 | 2019 | |
| Allergan, INC. | $23.16 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $19.16 | 2021 | |
| Merck Sharp & Dohme LLC | $17.29 | 2022 | |
| Shire North American Group INC | $13.73 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Chowdhury listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.